NI
TEVA icon

Noked Israel’s Teva Pharmaceuticals TEVA Stock Holding History

Noked Israel’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,485,000
Closed -$21M – 23
2024
Q1 		$21M Buy
1,485,000
+1,480,600
+33,650% +$18.7M 5.63% 8
2023
Q4 		$255K Buy
+4,400
New +$41.1K 0.07% 29

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Noked Israel's TEVA Position: Q2 2025 in Review

Noked Israel sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 209,606 shares — an estimated $3.22M sold.

Noked Israel first reported a position in TEVA in Q4 2018 and held it in 9 quarters. The position peaked at $72.4M in Q4 2024. 540 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Noked Israel reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Noked Israel sold 209,606 Teva Pharmaceuticals shares in Q2 2025, an estimated $3.22M.
  • Noked Israel first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 9 quarters.
  • Noked Israel's Teva Pharmaceuticals position peaked at $72.4M in Q4 2024.
  • 540 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Noked Israel's 13F filing for Q2 2025, filed 14 Aug 2025.